IMCR - Immunocore says new data demonstrates Kimmtrak efficacy for uveal melanoma
2024-06-01 11:38:04 ET
More on Immunocore
- Immunocore touts updated phase 1 results for melanoma asset brenetafusp
- Immunocore GAAP EPS of -$0.49 misses by $0.13, revenue of $70.5M beats by $1.32M
- Seeking Alpha’s Quant Rating on Immunocore
- Historical earnings data for Immunocore
- Financial information for Immunocore